Hetero to launch Covid drug Remdesivir under brand name Covifor in India

Covifor (Remdesivir) will be available in 100 mg vial (Injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner

Hyderabad-based Hetero Labs on Sunday said it had received regulatory approval to manufacture and market antiviral drug remdesivir for treating coronavirus patients.

Hetero's generic version of remdesivir will be marketed under the brand name 'Covifor' in India, said the company after getting approval from the Drug Controller General of India (DCGI).

“In the light of increasing Covid-19 cases in India, the approval of Covifor (Remdesivir) can prove to be a game-changer given its positive clinical outcomes. Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country," said B Partha